Compare T Rowe Price Group Inc (TROW) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T Rowe Price Group Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? T Rowe Price Group Inc trades at $99.49 (market cap $21.63B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: T Rowe Price Group Inc is far larger — about 4.4× Travere Therapeutics Inc. Common Stock's market cap, and T Rowe Price Group Inc pays a 5.13% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold T Rowe Price Group Inc for 115 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TROW | TVTX | |
|---|---|---|
Market Cap | $21.63B | $4.88B |
Volume | 2,302,405 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $121.68 | $67.52 |
52-Week Low | $86.19 | $26.79 |
Typical Hold Time | 115 Days | 0 Days |
Enterprise Value | $18.82B | $5.01B |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T. Rowe Price (TROW) trades at $99.62, down 4.2% today, with a bearish technical signal despite strong fundamentals including a 29.26% net income margin and 20.1% ROE. The stock shows attractive valuation with a P/E of 10.18 and P/B of 1.97, while recent earnings beat expectations in Q1 and Q2 2026. Assets under management reached $1.90 trillion in August 2026 despite net outflows, and the company maintains a strong dividend history with 40 years of consecutive increases.
TROW presents a value opportunity with solid profitability and dividend stability, though technical weakness and mixed analyst sentiment (21% buy, 63% hold) suggest near-term caution. The consensus price target of $110.50 implies 11% upside potential, but investors face risks from market-sensitive revenue and competitive pressures in asset management.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
